K ATP  Channel Pharmacogenomics: From Bench to Bedside | Zendy

Sattiraju S | Zendy; Reyes S | Zendy; Kane GC | Zendy; Terzic A | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

K ATP Channel Pharmacogenomics: From Bench to Bedside

Author(s) -

Sattiraju S,

Reyes S,

Kane GC,

Terzic A

Publication year - 2008

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/sj.clpt.6100378

Subject(s) - pharmacogenomics , clinical pharmacology , pharmacology , pharmacodynamics , pharmacokinetics , potassium channel , drug discovery , drug , pharmacogenetics , herg , channelopathy , systems pharmacology , medicine , computational biology , bioinformatics , biology , neuroscience , gene , genetics , genotype

Inheritance plays a significant role in defining drug response and toxicity. Advances in molecular pharmacology and modern genomics emphasize genetic variation in dictating inter‐individual pharmacokinetics and pharmacodynamics. A case in point is the homeostatic ATP‐sensitive potassium (K ATP ) channel, an established drug target that adjusts membrane excitability to match cellular energetic demand. There is an increased recognition that genetic variability of the K ATP channel impacts therapeutic decision‐making in human disease. Clinical Pharmacology & Therapeutics (2008) doi: 10.1038/sj.clpt.6100378

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research